뉴스
Genixcure Selected as Participating Company for Ewha Mokdong Hospital Open Lab Program
2026-03-27
Genixcure has been officially selected as a participating company in the Open Lab Program, supervised by the Ministry of Health and Welfare and hosted by Ewha Mokdong Hospital.
The Open Lab Program opens the hospital's advanced research infrastructure to companies within 10 years of founding, supporting joint research and product commercialization. For the 2026 program, a total of 27 companies were selected — 11 continuing from the first cohort and 16 newly joining — with Genixcure among the new entrants.
Through this collaboration, Genixcure will conduct: ▲ validation of brain tissue specificity linked to actual clinical conditions, ▲ evaluation of cellular and tissue-level delivery efficiency reflecting disease pathophysiology, and ▲ joint verification and advisory on clinical applicability. These efforts aim to advance Genixcure's current technology from the prototype stage to an enhanced stage that fully considers clinical translatability.
Building on this foundation, Genixcure is targeting the development of next-generation gene therapy candidates based on improved AAV vectors with superior efficacy and safety compared to existing global technologies. AI-based screening is expected to significantly reduce both the time and cost of research and development. Furthermore, the underlying platform technology is extensible beyond AAV to other viral vectors including Retrovirus and Lentivirus, enabling application across a broad range of indications such as central nervous system disorders, ocular diseases, and musculoskeletal and neuromuscular conditions.
Genixcure will leverage this program as a stepping stone to deepen its integration with the clinical setting and further strengthen its capabilities in developing gene therapies for rare diseases.